Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

2.600

-0.220 (-7.80%)

Sep 1, 2026, 4:00 PM EDT - Market closed

Virax Biolabs Group Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	6.44	4.23	3.59	9.35	0.02
Short-Term Investments	0.08	0.09	0.08	0.05	0.01
Cash & Short-Term Investments	6.52	4.32	3.67	9.4	0.03
Cash Growth	50.78%	17.91%	-61.00%	33774.24%	57.51%
Other Receivables	0.03	0.03	0.22	-	-
Receivables	0.03	0.03	0.22	-	-
Inventory	0.05	0.19	0.18	0.02	0.02
Prepaid Expenses	0.24	0.35	0.31	0.21	-
Total Current Assets	6.83	4.89	4.38	9.63	0.05
Property, Plant & Equipment	1.5	1.49	1.05	-	-
Other Intangible Assets	-	0.04	0.05	0.18	-
Total Assets	8.32	6.43	5.48	9.81	0.05

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	0.05	0.06	0.05	0.16	0.85
Accrued Expenses	0.52	0.53	0.08	0.55	0.4
Short-Term Debt	0.03	0.03	-	0.16	-
Current Portion of Leases	0.08	0.05	0.05	-	-
Current Unearned Revenue	-	-	-	0.04	-
Other Current Liabilities	-	-	-	-	0
Total Current Liabilities	0.69	0.67	0.17	0.91	1.25
Long-Term Leases	0.3	0.29	0.18	-	-
Total Liabilities	0.99	0.96	0.35	0.91	1.25

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	0.01	0	0	0	0
Retained Earnings	-29.61	-24.59	-18.53	-11.79	-6.34
Comprehensive Income & Other	37.18	30.28	23.89	20.92	5.36
Total Common Equity	7.58	5.7	5.37	9.13	-0.97
Minority Interest	-0.24	-0.23	-0.23	-0.22	-0.22
Shareholders' Equity	7.33	5.46	5.14	8.9	-1.2
Total Liabilities & Equity	8.32	6.43	5.48	9.81	0.05

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	0.41	0.38	0.22	0.16	-
Net Cash (Debt)	6.1	3.95	3.44	9.24	0.03
Net Cash Growth	54.68%	14.64%	-62.73%	33181.39%	-
Net Cash Per Share	15.35	26.45	42.89	217.25	0.73
Filing Date Shares Outstanding	0.58	0.17	0.1	0.07	0.04
Total Common Shares Outstanding	0.58	0.17	0.1	0.06	0.04
Working Capital	6.14	4.22	4.21	8.73	-1.2
Book Value Per Share	13.08	32.80	52.13	146.76	-24.42
Tangible Book Value	7.58	5.66	5.32	8.95	-0.97
Tangible Book Value Per Share	13.08	32.57	51.64	143.89	-24.42
Machinery	1.85	1.49	0.9	0.01	-

SEC Filings: 10-K · 10-Q